From: Glucocorticoid use in psoriatic arthritis and treatment outcomes: does the gender have a role?
Variable | Dose | Duration |
---|---|---|
Age | 0.057 | 0.197 |
Gender | 0.054 | 0.159 |
Duration | 0.292 | 0.298 |
DIP involvement | 0.139 | 0.327 |
Large joint involvement | 0.962 | 0.962 |
Enthesitis | 0.065 | 0.480 |
Dactylitis | 0.034* | 0.630 |
Axial involvement | 0.503 | 0.609 |
Nail psoriasis | 0.628 | 0.628 |
Pustular psoriasis | 0.645 | 0.645 |
TJS | 0.264 | 0.000* |
SJS | 0.300 | 0.027* |
CRP | 0.003* | 0.006* |
DAS 28 | 0.031* | 0.000* |
DAPSA | 0.021* | 0.000* |
GC dose | NA | 0.000* |
GC duration | 0.000* | NA |